 |
||||||||
|
|
|
 |
|
|
|
|
|
|
INGLEWOOD |
|||||
 |
|||||
V E N T U R E S |
|||||
|
|
|
|
Helping Healthcare Entrepreneurs Succeed |
|||
12526 High Bluff Drive |
|||
|
|
|
M. Blake Ingle, Ph.D. Dr. Ingle was formerly CEO of IMCERA Group, a Fortune 250 healthcare company. He has over thirty years of healthcare experience, including CEO of Canji, a biotech company that was sold to Schering-Plough in a successful transition for its venture capital investors. Dr. Ingle also serves on the Board of Directors of Vical, Dendreon Corporation, Cengent Therapeutics, Alerion, Targeted Molecules Corp., INEX Pharmaceuticals, and serves as Strategic Advisor for Quorex Pharmaceuticals, and is a recent past Chairman of the Burnham Institute (formerly the La Jolla Cancer Research Foundation). Dr. Ingle's Ph.D. is in Microbiology. He may be contacted at blake@inglewoodventures.com .
Daniel C. Wood, CFA Mr. Wood has over 26 years of business experience in San Diego as an investment advisor, primarily to local, key technology executives. From 1987 until 2000, he also published the Sorrento Valley/Golden Triangle Business News for which he interviewed over 200 CEOs of major life sciences and other technology companies in San Diego. Dan was named a Top 25 Biotech Venture Capitalist in the Nation by Venture Reporter. Mr. Wood is a Tufts graduate, and holds an MBA in Finance and the Chartered Financial Analyst designation. He currently serves on the Board of Directors of CardioNet and Cylene Pharmaceuticals, where he lead the first institutional rounds of financing, and as a Board Observer at Conforma Therapeutics, and for 3.5 years until its June 2004, IPO, Digirad [DRAD - NASDAQ]. He may be contacted at dan@inglewoodventures.com
|
